Interlink provides Januvia pre-launch med ed
Interlink Healthcare Communications will provide pre-launch medical education for Merck’s Januvia (sitagliptin), a DPP-4 inhibitor for treating type II diabetes.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.